Fig. 5.

Combination of MVA-CD40L and tumor-targeting antibodies enhances tumor growth control. a–d Enhanced tumor growth control when rMVA-CD40L immunization is combined with tumor-targeting antibodies. a, b B16.OVA tumor-bearing mice received PBS or were immunized with 5 × 10⁷ TCID₅₀ of rMVA-CD40L (Day 0). Mice received 200 µg of either IgG2a or anti-TRP-1 antibody i.p. at days −2, 2, 6, and 10. a Tumor size follow-up (n = 5 mice/group) and b overall survival. c, d Balb/c mice bearing 85–100 mm³ CT26.HER2 received PBS or were immunized with 5 × 10⁷ TCID₅₀ of MVA-HER2-CD40L (Day 0). Mice received 5 µg of either IgG1 or anti-HER2 antibody i.p. at days –2, 1, and 4. c Tumor size follow-up (n = 5 mice/group) and d overall survival. Data in a and c are expressed as mean ± SEM, representative of at least two independent experiments. One-way ANOVA was performed on a. Log-rank test on mouse survival was performed for b. *p < 0.05; **p < 0.01; ***p < 0.005